Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Interferon Lambda vs Alfa-2a in Chronic Hepatitis C
NCT01447394Phase 3Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2012
- Primary completion
- Mar 2014
- Modality
- Cytokines & Interferons
- Countries
- 20
01
Overview
A Phase 3 trial of peginterferon lambda-1a in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Planned start Mar 2012; status: withdrawn.
02
Drugs
peginterferon lambda-1a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01447394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01447394.